Deerfield Management’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-3,723,131
| Closed | -$79.8M | – | 86 |
|
|
2026
Q1 | $79.8M | Hold |
3,723,131
| – | – | 0.94% | 34 |
|
|
2025
Q4 | $34.7M | Sell |
3,723,131
-982,282
| -21% | -$8.21M | 0.44% | 46 |
|
|
2025
Q3 | $33.2M | Buy |
4,705,413
+982,282
| +26% | +$6.76M | 0.51% | 46 |
|
|
2025
Q2 | $24.2M | Buy |
3,723,131
+762,391
| +26% | +$5.24M | 0.44% | 46 |
|
|
2025
Q1 | $23.5M | Buy |
2,960,740
+364,707
| +14% | +$3.93M | 0.46% | 45 |
|
|
2024
Q4 | $32.9M | Sell |
2,596,033
-21,680
| -0.8% | -$302K | 0.62% | 39 |
|
|
2024
Q3 | $36.5M | Sell |
2,617,713
-305,424
| -10% | -$4.36M | 0.54% | 43 |
|
|
2024
Q2 | $40.3M | Buy |
2,923,137
+1,157,825
| +66% | +$16.9M | 0.67% | 37 |
|
|
2024
Q1 | $29.2M | Buy |
1,765,312
+4,134
| +0.2% | +$61.9K | 0.51% | 40 |
|
|
2023
Q4 | $25.7M | Buy |
1,761,178
+491,186
| +39% | +$5.95M | 0.47% | 41 |
|
|
2023
Q3 | $15.6M | Hold |
1,269,992
| – | – | 0.34% | 49 |
|
|
2023
Q2 | $15.2M | Buy |
+1,269,992
| New | +$16.6M | 0.32% | 56 |
|
|
2023
Q1 | – | Sell |
-964,033
| Closed | -$20.7M | – | 108 |
|
|
2022
Q4 | $20.7M | Sell |
964,033
-67,967
| -7% | -$1.39M | 0.43% | 60 |
|
|
2022
Q3 | $20.7M | Sell |
1,032,000
-2,480,123
| -71% | -$52.7M | 0.41% | 63 |
|
|
2022
Q2 | $62.9M | Buy |
3,512,123
+1,425,674
| +68% | +$14.7M | 1.3% | 25 |
|
|
2022
Q1 | $20.7M | Sell |
2,086,449
-116,084
| -5% | -$1.53M | 0.46% | 50 |
|
|
2021
Q4 | $37.1M | Buy |
2,202,533
+491,803
| +29% | +$10.1M | 0.78% | 38 |
|
|
2021
Q3 | $40.6M | Buy |
1,710,730
+891,750
| +109% | +$21.4M | 0.79% | 38 |
|
|
2021
Q2 | $18.6M | Buy |
+818,980
| New | +$17.1M | 0.33% | 86 |
|
Other funds holding DAWN
Deerfield Management's DAWN Position: Q2 2026 in Review
Deerfield Management sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 3,723,131 shares — an estimated $79.8M sold.
Deerfield Management first reported a position in DAWN in Q2 2021 and held it in 19 quarters. The position peaked at $79.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Deerfield Management reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Deerfield Management sold 3,723,131 Day One Biopharmaceuticals shares in Q2 2026, an estimated $79.8M.
- Deerfield Management first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 19 quarters.
- Deerfield Management's Day One Biopharmaceuticals position peaked at $79.8M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.